Decision-making and autonomy among participants in early-phase cancer immunotherapy trials: a qualitative study
Abstract Background Participants considering early-phase cancer clinical trials (CTs) need to understand the unique risks and benefits prior to providing informed consent. This qualitative study explored the factors that influence patients’ decisions about participating in early-phase cancer immunot...
Main Authors: | Jonathan Avery, Jennifer A.H. Bell, Khotira Baryolay, Gary Rodin, Rinat Nissim, Lynda G. Balneaves |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-03-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-024-12119-7 |
Similar Items
-
Gatekeeping in cancer clinical trials in Canada: The ethics of recruiting the “ideal” patient
by: Jennifer A. H. Bell, et al.
Published: (2020-06-01) -
The proportion of randomized controlled trials that inform clinical practice
by: Nora Hutchinson, et al.
Published: (2022-08-01) -
Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer
by: Daniel J. García-Domínguez, et al.
Published: (2024-01-01) -
The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials
by: Colt Williams, MD, et al.
Published: (2023-12-01) -
Willingness to participate in pragmatic dialysis trials: the importance of physician decisional autonomy and consent approach
by: Katherine R. Courtright, et al.
Published: (2017-10-01)